Inhibition of human IAPP fibril formation does not prevent β-cell death: Evidence for distinct actions of oligomers and fibrils of human IAPP

American Journal of Physiology - Endocrinology and Metabolism

Volumn 291, Issue 6, 2006, Pages

  Meier, Juris J ^a   Kayed, Rakez ^b   Lin, Chia Yu ^a   Gurlo, Tatyana ^a   Haataja, Leena ^a   Jayasinghe, Sajith ^c   Langen, Ralf ^c   Glabe, Charles G ^b   Butler, Peter C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Human islet amyloid polypeptide; Islet amyloid polypeptide; Rifampicin

Indexed keywords

AMYLIN; AMYLOID; OLIGOMER; RIFAMPICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADENOVIRIDAE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DEATH; COLORING AGENTS; DNA, COMPLEMENTARY; FLUORESCENT DYES; HUMANS; IN SITU NICK-END LABELING; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; PROPIDIUM; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; TETRAZOLIUM SALTS; THIAZOLES;

EID: 33845467504     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00082.2006     Document Type: Article

References (35)

1. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3: 108-127, 1978.
2. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361: 1642-1644, 2003.
3. Beattie GM, Cirulli V, Lopez AD, and Hayek A. Ex vivo expansion of human pancreatic endocrine cells. J Clin Endocrinol Metab 82: 1852-1856, 1997.
4. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, and Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53: 1509-1516, 2004.
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, and Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110, 2003.
6. Butler AE, Janson J, Soeller WC, and Butler PC. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52: 2304-2314, 2003.
7. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, and Turner RC. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9: 151-159, 1988.
8. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, and Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628-8632, 1987.
9. Glabe CG and Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, 2 Suppl 1: S74-S78, 2006.
10. Glenner GG and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890, 1984.
11. Hull RL, Westermark GT, Westermark P, and Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89: 3629-3643, 2004.
12. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, and Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475, 1995.
13. Janson J, Ashley RH, Harrison D, McIntyre S, and Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48: 491-498, 1999.
14. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, and Butler PC. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93: 7283-7288, 1996.
15. Kahn SE, Andrikopoulos S, and Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48: 241-253, 1999.
16. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, and Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489, 2003.
17. Lacy PE and Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35-39, 1967.
18. Li J, Zhu M, Rajamani S, Uversky VN, and Fink AL. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11: 1513-1521, 2004.
19. Lin CY, Gurlo T, Haataja L, Hsueh WA, and Butler PC. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 90: 6678-6686, 2005.
20. Lingohr MK, Dickson LM, McCuaig JF, Hugl SR, Twardzik DR, and Rhodes CJ. Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 51: 966-976, 2002.
21. Lorenzo A, Razzaboni B, Weir GC, and Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368: 756-760, 1994.
22. Meier JJ, Ritzel RA, Maedler K, Gurlo T, and Butler PC. Increased vulnerability of newly forming beta-cells to cytokine-induced cell death. Diabetologia 49: 83-89, 2005.
23. Namba Y, Kawatsu K, Izumi S, Ueki A, and Ikeda K. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet 340: 978, 1992.
24. O'Brien TD, Butler AE, Roche PC, Johnson KH, and Butler PC. Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes 43: 329-336, 1994.
25. O'Brien TD, Butler PC, Kreutter DK, Kane LA, and Eberhardt NL. Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. Am J Pathol 147: 609-616, 1995.
26. O'Brien TD, Butler PC, Westermark P, and Johnson KH. Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol 30: 317-332, 1993.
27. Ono K and Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97: 105-115, 2006.
28. Opie EL. The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med 5: 527-540, 1901.
29. Ritzel RA and Butler PC. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52: 1701-1708, 2003.
30. Tomiyama T, Asano S, Suwa Y, Morita T, Kataoka K, Mori H, and Endo N. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun 204: 76-83, 1994.
31. Tomiyama T, Kaneko H, Kataoka K, Asano S, and Endo N. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J 322: 859-865, 1997.
32. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, and Endo N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 271: 6839-6844, 1996.
33. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, and Kahn SE. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93: 3492-3496, 1996.
34. Wang F, Hull RL, Vidal J, Cnop M, and Kahn SE. Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50: 2514-2520, 2001.
35. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, and Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84: 3881-3885, 1987.